Table 1. Patient and baseline disease characteristics (n=73).
| Median age (years) (range) | 52 (33–74) |
| KPS, no. (%) of patients | |
| 100 | 31 (42) |
| 90 | 19 (26) |
| 80 | 15 (21) |
| 70 | 7 (10) |
| 60 | 1 (1) |
| Number of metastatic sites, no. (%) of patientsa | |
| 1 | 26 (36) |
| 2 | 25 (34) |
| ⩾3 | 21 (29) |
| Sites of metastasis, no. (%) of patientsa | |
| Bone | 33 (45) |
| Liver | 32 (44) |
| Lymph nodes | 29 (40) |
| Lung | 25 (34) |
| Prior chemotherapy | |
| Anthracyclines, no. (%) of patients | 73 (100) |
| (Neo)adjuvant setting | 42 (58) |
| Metastatic setting | 34 (47) |
| Docetaxel, no. (%) of patients | 11 (15) |
| Cyclophosphamide, no. (%) of patients | 38 (52) |
| 5-FU, no. (%) of patients | 31 (42) |
a
Confirmation of metastatic disease was not available in one patient. KPS=Karnofsky performance status; 5-FU=5-fluorouracil.